Abzena has augmented its antibody drug conjugation (ADC) and biologics (including mono and bispecific antibodies) development services with the launch of ADC Cascade and Biologics Cascade. These ex-vivo platform approaches allow efficacy and safety studies against clinically characterized on and off-target tissues.   Clinical failure of ADCs and biologics remain high, and candidate lead selection is associated with significant risk for translation into clinical development. Pre-clinical testing ...